Literature DB >> 7812070

Osteoporosis-2044.

R P Heaney.   

Abstract

It is likely that by 2044 biomedical and public health forces will be able to control bony fragility to a substantially greater degree than we have succeeded in doing today, but that demographic and lifestyle forces already at work will offset those gains, perhaps substantially. On the other hand, economic and social forces outside of our control will decrease the prevalence of skeletal fragility--harshly, I fear--either by strengthening old bones the hard way, or by decreasing the numbers of the elderly, or both. The final outcome will be the algebraic sum of the effects of these countervailing forces, which is impossible to estimate with any assurance. My guess is that osteoporosis will be less of a problem in 2044, though, unfortunately, for the wrong reasons.

Entities:  

Mesh:

Year:  1994        PMID: 7812070     DOI: 10.1007/bf01623346

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  11 in total

1.  Sickle cell anemia a molecular disease.

Authors:  L PAULING; H A ITANO
Journal:  Science       Date:  1949-11-25       Impact factor: 47.728

2.  Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations?

Authors:  K J Obrant; U Bengnér; O Johnell; B E Nilsson; I Sernbo
Journal:  Calcif Tissue Int       Date:  1989-03       Impact factor: 4.333

Review 3.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.

Authors: 
Journal:  Am J Med       Date:  1993-06       Impact factor: 4.965

Review 4.  Anabolic actions of parathyroid hormone on bone.

Authors:  D W Dempster; F Cosman; M Parisien; V Shen; R Lindsay
Journal:  Endocr Rev       Date:  1993-12       Impact factor: 19.871

5.  Menopausal estrogen therapy and hip fractures.

Authors:  A Paganini-Hill; R K Ross; V R Gerkins; B E Henderson; M Arthur; T M Mack
Journal:  Ann Intern Med       Date:  1981-07       Impact factor: 25.391

6.  Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study.

Authors:  T Naessén; I Persson; H O Adami; R Bergström; L Bergkvist
Journal:  Ann Intern Med       Date:  1990-07-15       Impact factor: 25.391

7.  Vitamin D3 and calcium to prevent hip fractures in elderly women.

Authors:  M C Chapuy; M E Arlot; F Duboeuf; J Brun; B Crouzet; S Arnaud; P D Delmas; P J Meunier
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

8.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

Authors:  D P Kiel; D T Felson; J J Anderson; P W Wilson; M A Moskowitz
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

9.  Annual injection of vitamin D and fractures of aged bones.

Authors:  R J Heikinheimo; J A Inkovaara; E J Harju; M V Haavisto; R H Kaarela; J M Kataja; A M Kokko; L A Kolho; S A Rajala
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

10.  Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial.

Authors:  C Y Pak; K Sakhaee; V Piziak; R D Peterson; N A Breslau; P Boyd; J R Poindexter; J Herzog; A Heard-Sakhaee; S Haynes; B Adams-Huet; J S Reisch
Journal:  Ann Intern Med       Date:  1994-04-15       Impact factor: 25.391

View more
  3 in total

1.  Hip fractures in France: the magnitude and perspective of the problem.

Authors:  C Baudoin; P Fardellone; B Thelot; R Juvin; V Potard; K Bean; J L Sebert
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

2.  The bone care nurse project.

Authors:  Cristiana Casentini; Giuseppe Chiaramonti; Antonietta Amedei; Federica Cioppi; Alberto Falchetti; Laura Masi; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

Review 3.  Exercise prescription after fragility fracture in older adults: a scoping review.

Authors:  L M Feehan; C A Beck; S R Harris; D L MacIntyre; L C Li
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.